AzTrials
AzTrials

Schizophrenia Spectrum and Other Psychotic DisordersNCT06040944

Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients

An observational study of Schizophrenia Spectrum and Other Psychotic Disorders and Periodontal Diseases, run by Fayoum University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of the present cohort retrospective study is to explore the effect of antipsychotics on periodontal health and the possible effect of antipsychotic-induced hyperprolactinemia as a risk factor for periodontal disease progression in schizophrenic patients. Read more about this study

Who is it for?
Ages 20 years and older
What is being tested?
antipsychotic drugs inducing hyperprolactinemia
How many people
64 participants
Where
1 siteEgypt
Study dates
1 Sep 2022to 1 Nov 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 years and older
  • All sexes
  • Adult, Older adult

Study population: diagnosis of schizophrenia according to DSM-IV-TR criteria for schizophrenia

Who may be able to join

  • with the diagnosis of schizophrenia
  • over 20 years old
  • did not receive any periodontal treatment for the past year
  • with at least 20 remaining teeth.

Who cannot join

  • with systemic condition that may affect periodontal status such as; DM, cardiovascular diseases, metabolic syndrome, osteoporosis, AIDS and chronic alcoholism
  • having local factors that may aggravate and predispose for periodontal diseases such as; orthodontic and prosthetic appliances, parafunctional habits, and heavy smoking
  • receiving any systemic medication and/or systemic antibiotics for the past 6 months.
  • patients undergoing any type of periodontal treatment for the past year and
  • within childhood and adolescence psychiatry section.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Rania Hassan Shalby

    Giza

Other trials in Egypt

About this study

Official title: The Effect of Antipsychotic Medication and the Associated Hyperprolactinemia as Risk Factor for Periodontal Diseases in Schizophrenic Patients: a Cohort Retrospective Study

The aim of the present cohort retrospective study is to explore the effect of antipsychotics on periodontal health and the possible effect of antipsychotic-induced hyperprolactinemia as a risk factor for periodontal disease progression in schizophrenic patients.

The study population consisted of three groups: Group A (n = 21): schizophrenic patients who have been taking "prolactin inducing" antipsychotics for at least 1 year, Group B (n = 21): schizophrenic patients who have been taking "prolactin sparing" antipsychotics for at least 1 year and Group C (n = 22): newly diagnosed schizophrenic patients and/or patients who did not receive any psychiatric treatment for at least 1 year.

The study groups underwent an assessment of periodontal condition in terms of pocket depth (PD), clinical attachment loss (CAL), gingival recession, tooth mobility, and bleeding on probing (BOP). Also, bone mineral density was evaluated using DEXA scans and the serum prolactin level was measured by automated immunoassay.

Read the detailed description

Background and objective: The aim of the present cohort retrospective study is to explore the effect of antipsychotics on periodontal health and the possible effect of antipsychotic-induced hyperprolactinemia as a risk factor for periodontal disease progression in schizophrenic patients.

Methods

  1. Study design and setting: The current study is a cohort retrospective study that will be performed on schizophrenic patients. All subjects will be recruited from the outpatient clinic of the department of Psychiatry-Faculty of Medicine- MUST University. The patients' database from the department of psychiatry will be filtered, and all patients with a diagnosis of schizophrenia according to DSM-IV-TR criteria for schizophrenia and fulfilling eligibility criteria will be contacted. Also, outpatients newly diagnosed with schizophrenia will be included. Those who agree to be enrolled in the study will sign a written informed consent. For patients previously diagnosed with schizophrenia, medication data will be acquired from prescription files, including the type and duration of the prescribed antipsychotic or other medications. Psychiatric assessment and recording of demographic variables such as age, gender, duration of psychiatric disease, and type and duration of antipsychotic medication will be performed by the second investigator (EM.A). Then, all subjects will be referred, with their records and files, to the Faculty of Dentistry at ACU University for periodontal assessment and sample collection.
  2. Eligibility criteria: The included patients are those: 1) with the diagnosis of schizophrenia; 2) over 20 years old; 3) who did not receive any periodontal treatment for the past year; and 4) with at least 20 remaining teeth. To avoid potential confounding factors, the excluded patients are: 1) those with systemic conditions that may affect periodontal status such as; DM, CVS, metabolic syndrome, osteoporosis, AIDS, and chronic alcoholism (3, 4, 17); 2) those with local factors that may aggravate and predispose for periodontal diseases, such as orthodontic and prosthetic appliances, parafunctional habits, and heavy smoking (4, 23-25); and 3) those receiving any systemic medication and/or systemic antibiotics for the past 6 months. Additionally, exclusion criteria involved 4) patients undergoing any type of periodontal treatment for the past year; 5) patients within the childhood and adolescent psychiatry section; and 6) patients who received antipsychotic medication for ≥ 12 months.
  3. Estimating the sample size: The sample size was calculated considering type I error (α) of 0.05 and power (1-β) of 0.9. Based on a previous study by (16) that used proportions, inequality, and two independent groups (Fisher's exact test) to compare patients with a pocket depth of 4 mm to those with no pocket depth identified in patients receiving antipsychotics 12 months with effect size, the sample size was calculated and found to be a total of 64 patients. The application G*Power 3.1.9.7 [16] was used to determine the sample size needed for the study.
  4. Participants:

The study population will be divided into three groups: Exposure groups will be divided according to their "prolactin-inducing" or "prolactin sparing" effect (26-36). Group A (n = 21): schizophrenic patients that have been taking antipsychotic medication that may induce hyperprolactinemia (FGAs and SGAs; amisulpride, risperidone, and paliperidone) for at least 1 year, group B (n = 21): schizophrenic patients who have been taking antipsychotics that do not have a significant effect on serum prolactin levels (in SGAs, clozapine, quetiapine, olanzapine, ziprasidone, and aripiprazole) for at least 1 year and Group C (n = 22): newly diagnosed schizophrenic patients and/or patients who did not receive any psychiatric treatment for at least 1 year.

[4] Outcome measurements: The primary outcome was the assessment of periodontal condition in all study groups measured in terms of pocket depth (PD), tooth mobility, clinical attachment loss (CAL), gingival recession, and bleeding on probing (BOP), while the secondary outcomes were evaluation of BMD and the serum prolactin level (measured by automated immunoassay in ng/ml).

[6]Assessment of clinical data and patient condition: Assessment of mental health: The Positive and Negative Syndrome Scale (PNSS) (37) was used to evaluate each patient's clinical history and current mental health state.

Periodontal evaluation:

All teeth were evaluated and recorded. The means for the following parameters were computed: pocket depth (PD), clinical attachment loss (CAL), and bleeding on probing (BOP) (38, 39). Using a manual periodontal probe (Williams' periodontal probe, PCP-12; Hu-Friedy, Chicago, IL, USA), PD and CAL measurements were collected on six surfaces per tooth (mesio-buccal, mid-buccal, disto-buccal, and mesio-lingual, mid-lingual, disto-lingual, or palatal surface).While CAL measures the distance between the cement-enamel junction of the tooth and the deepest aspect of the pocket, probing pocket depth measures the distance between the gingival margin and the deepest part of the pocket. Total mean PD of the six locations for each tooth was computed for each patient and distance was recorded to the nearest millimeter (40). Sulcus depths between 0 and 2 mm were regarded as normal (41). Gingival recession was measured from the CEJ to the marginal border of the soft tissue on the buccal and lingual sides of each tooth. The total mean number of recessions per tooth for each patient was used to record tooth recessions. Gingival recession, if present, was only used to calculate CAL by its addition to PD.

Four surfaces per tooth were examined for BOP readings (mesial, distal, buccal, and lingual or palatal surface). Bleeding on probing was examined directly after the PD measurement and was reported as absent (0) or present (1). 30 seconds after applying the periodontal probe). The proportion of teeth displaying BOP was recorded.

Generalized mild periodontitis is defined as >30% of remaining teeth with PD 5 mm and 7 mm, as per the 2015 Update to the 1999 Classification of Periodontitis. Severe periodontitis was defined as a probing depth (PD) of 7 mm, with localised periodontitis involving 30% of remaining teeth and generalised periodontitis involving >30% of remaining teeth (42) .

Assessment of bone mineral density:

Dual-energy X-ray absorptiometry (DEXA scan) is an advanced technology that could detect bone mineral density. The GE Lunar Prodigy densitometer was used to perform this test.To determine what constitutes healthy bone, we utilized the World Health Organization's criteria: a T score of -1 indicates normal bone, a T score between -1 and -2.5 indicates osteopaenia, and a T score of -2.5 indicates osteoporosis.

Measurement of serum prolactin level:

Blood will be withdrawn from all patients to determine the fasting serum prolactin level. Prolactin concentrations in blood will be measured in a faculty laboratory by automated immunoassay methodology (43).

7] Data collection and management: Periodontal assessment will be carried out by the primary investigator (S.R.), who will be unaware of the patient's psychological status and records (to avoid potential bias). The third investigator (M.C.) will collect all patient records to perform the final analysis.

STATISTICAL METHODS:

Quantitative (continuous) variables were expressed as mean ± SD. As the quantitative variables were not normally distributed, the Kruskal-Wallis test (a non-parametric test) was used to compare them among the 3 study groups. A post hoc analysis was done for variables that showed a statistically significant difference in the Kruskal-Wallis test using Dwass-Steel-Critchlow-Fligner pairwise comparisons. As for qualitative variables (categorical), the chi-square test was used to compare them among the 3 study groups, and values were expressed as percentages. Also, linear regression analysis was performed to study the relation between 2 quantitative variables (serum prolactin level and PD measurements), while ordinal logistic regression was used to relate one quantitative (serum prolactin level) and one qualitative (BMD or grades of periodontitis) variables.

Being tested
antipsychotic drugs inducing hyperprolactinemia
Keywords
schizophrenia, antipsychotics, periodontal disease, hyperprolactinemia
Medical subject headings
Schizophrenia Spectrum and Other Psychotic Disorders, Periodontal Diseases, Schizophrenia, Hyperprolactinemia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • antipsychotic drugs inducing hyperprolactinemiaDrug

    Also called antipsychotic drugs not inducing hyperprolactinemia

    not exposed

Study groups in NCT06040944
Study groupRoleWhat they receive
Exposure 1Schizophrenic patients that have been taking antipsychotic drugs inducing hyperprolactinemia (FGAs and the SGAs; amisulpride, risperidone and paliperidone) for at least 1 year
Receives: Drug: antipsychotic drugs inducing hyperprolactinemia
Exposure 2Schizophrenic patients that have been taking antipsychotics sparing hyperprolactinemia (In SGAs; clozapine, quetiapine, olanzapine, ziprasidone and aripiprazole) for at least 1 year
Non exposure (basline)Newly diagnosed schizophrenic patients and/ or patients did not receive any psychiatric treatment for at least 1 year

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Severity of periodontal diseases

    The primary outcome will be the assessment of periodontal condition in all study groups measured in terms of Pocket depth (PD), clinical attachment loss (CAL) (both measured using graduated periodontal probe in mm)

    Measured: 1 months

  2. gingival condition

    bleeding on probing (BOP) using scores from 0-3

    Measured: 1 months

  3. tooth mobility

    in mm

    Measured: 1 months

Secondary outcomes (1)
  1. Serum prolactin level

    measurement of serum prolactin level ( measured by automated immunoassay in ng/ml)

    Measured: 1 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Sep 2023
  2. Study start1 Sep 2022
  3. Primary completion1 Oct 2022
  4. Study completion1 Nov 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
64 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06040944
Sponsor's protocol ID
19038219038211011
Status last verified
Sep 2023
First submitted
10 Mar 2023
Last updated
18 Sep 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Schizophrenia Spectrum and Other Psychotic Disorders and Periodontal Diseases, run by Fayoum University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Severity of periodontal diseases (time frame: 1 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in